Is PANCYTOPENIA a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed PANCYTOPENIA.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 25 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported PANCYTOPENIA to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and PANCYTOPENIA. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause PANCYTOPENIA, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes PANCYTOPENIA. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if PANCYTOPENIA ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing PANCYTOPENIA: 25
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where PANCYTOPENIA is a reported side effect: 0.7510%

FDA reports of any drug causing PANCYTOPENIA : 20153
Average percentage for all medicated patients where PANCYTOPENIA is reported as a complication: 0.1263%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
DESMOID TUMOUR ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
ANGINA PECTORIS ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
SARCOMA ( 1 patients )
GERM CELL CANCER ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with PANCYTOPENIA:

REVLIMID (2362 patients)
ASPIRIN (1613 patients)
METHOTREXATE (1549 patients)
DEXAMETHASONE (1536 patients)
ZOMETA (1323 patients)
PREDNISOLONE (1283 patients)
PREDNISONE (1221 patients)
CYCLOPHOSPHAMIDE (1178 patients)
LASIX (1132 patients)
FOLIC ACID (993 patients)
AREDIA (936 patients)
REMICADE (890 patients)
CARBOPLATIN (820 patients)
OMEPRAZOLE (808 patients)
DECADRON (794 patients)
FUROSEMIDE (790 patients)
ALLOPURINOL (787 patients)
VELCADE (754 patients)
ACETAMINOPHEN (738 patients)
NEUPOGEN (694 patients)
COUMADIN (681 patients)
GLEEVEC (671 patients)
CISPLATIN (641 patients)
ACYCLOVIR (627 patients)
CYTARABINE (625 patients)
CYCLOSPORINE (624 patients)
ETOPOSIDE (615 patients)
PROTONIX (615 patients)
NEXIUM (597 patients)
ZOFRAN (595 patients)
POTASSIUM CHLORIDE (580 patients)
BACTRIM (572 patients)
VANCOMYCIN (567 patients)
ATIVAN (558 patients)
ARANESP (552 patients)
PREDNISONE TAB (549 patients)
VINCRISTINE (547 patients)
THALIDOMIDE (539 patients)
FLUOROURACIL (513 patients)
PRILOSEC (503 patients)
NEURONTIN (490 patients)
LISINOPRIL (489 patients)
FLUCONAZOLE (486 patients)
LIPITOR (484 patients)
LEVAQUIN (484 patients)
EXJADE (465 patients)
OXYCONTIN (460 patients)
AMBIEN (455 patients)
LORAZEPAM (447 patients)
FOSAMAX (447 patients)
MORPHINE (446 patients)
ATENOLOL (441 patients)
NEORAL (427 patients)
RIBAVIRIN (426 patients)
CIPROFLOXACIN (424 patients)
NORVASC (419 patients)
VIOXX (416 patients)
DOXORUBICIN HCL (409 patients)
MYCOPHENOLATE MOFETIL (408 patients)
SIMVASTATIN (406 patients)
COMPAZINE (399 patients)
GABAPENTIN (399 patients)
OXYCODONE HCL (391 patients)
DIFLUCAN (385 patients)
PEGASYS (382 patients)
SYNTHROID (378 patients)
RITUXIMAB (375 patients)
WARFARIN SODIUM (374 patients)
VICODIN (369 patients)
FAMOTIDINE (357 patients)
AZATHIOPRINE (356 patients)
ALIMTA (352 patients)
PERCOCET (351 patients)
HUMIRA (348 patients)
PLAVIX (348 patients)
IBUPROFEN (345 patients)
AMLODIPINE (344 patients)
LEVOTHYROXINE SODIUM (344 patients)
SOLIRIS (342 patients)
LYRICA (339 patients)
METHYLPREDNISOLONE (326 patients)
VITAMIN B-12 (324 patients)
PROCRIT (319 patients)
VIDAZA (319 patients)
TACROLIMUS (317 patients)
ZOLOFT (315 patients)
PROCRIT /00909301/ (309 patients)
METOPROLOL TARTRATE (308 patients)
LANSOPRAZOLE (305 patients)
ZYVOX (304 patients)
RITUXAN (299 patients)
PREDONINE (298 patients)
PROGRAF (298 patients)
FLUDARABINE PHOSPHATE (297 patients)
HYDROCHLOROTHIAZIDE (295 patients)
LOVENOX (294 patients)
AUGMENTIN '125' (293 patients)
SOLU-MEDROL (292 patients)
PREVACID (290 patients)
ALBUTEROL (290 patients)
DIGOXIN (290 patients)
GEMZAR (288 patients)
CYTOXAN (286 patients)
ZITHROMAX (285 patients)
NEULASTA (284 patients)
XANAX (283 patients)
TAXOTERE (282 patients)
VITAMIN D (281 patients)
ZANTAC (281 patients)
INSULIN (280 patients)
COPEGUS (279 patients)
KEPPRA (277 patients)
LEXAPRO (273 patients)
ENBREL (272 patients)
ADRIAMYCIN PFS (272 patients)
HEPARIN SODIUM INJECTION (271 patients)
ZOCOR (270 patients)
CHEMOTHERAPEUTICS NOS (268 patients)
CAMPATH (264 patients)
LEVOFLOXACIN (263 patients)
MULTI-VITAMINS (263 patients)
ZYPREXA (262 patients)
FLOMAX (261 patients)
CIPRO (257 patients)
EPOGEN (256 patients)
TAXOL (254 patients)
REGLAN (252 patients)
MELPHALAN HYDROCHLORIDE (251 patients)
METFORMIN HCL (250 patients)
RADIATION THERAPY (249 patients)
MEGACE (248 patients)
CELEBREX (247 patients)
TEGRETOL (246 patients)
SEROQUEL (245 patients)
MAGNESIUM OXIDE (243 patients)
ONDANSETRON (242 patients)
THALOMID (242 patients)
FENTANYL (242 patients)
DIOVAN (238 patients)
RHEUMATREX (238 patients)
LANTUS (237 patients)
HEPARIN (237 patients)
PAXIL (237 patients)
TOPROL-XL (236 patients)
ROCEPHIN (235 patients)
DEXAMETHASONE TAB (232 patients)
PANTOPRAZOLE SODIUM (232 patients)
FLUDARA (231 patients)
CALCIUM (231 patients)
XELODA (230 patients)
CALCIUM CARBONATE (228 patients)
HYDROCORTISONE (227 patients)
KALETRA (226 patients)
NYSTATIN (224 patients)
LORTAB (224 patients)
PEPCID (223 patients)
PACLITAXEL (220 patients)
DILAUDID (216 patients)
TEMODAL (216 patients)
FLAGYL (216 patients)
AMOXICILLIN (215 patients)
TASIGNA (213 patients)
RISPERDAL (212 patients)
MORPHINE SULFATE (211 patients)
NITROGLYCERIN (211 patients)
FERROUS SULFATE TAB (210 patients)
RAMIPRIL (210 patients)
MS CONTIN (208 patients)
RANITIDINE (208 patients)
DEPAKENE (206 patients)
CLARITHROMYCIN (206 patients)
NPLATE (205 patients)
DOXIL (205 patients)
PEG-INTRON (204 patients)
AMITRIPTYLINE HCL (203 patients)
SPIRONOLACTONE (201 patients)
AVASTIN (201 patients)
CHLORHEXIDINE GLUCONATE (200 patients)
VALTREX (199 patients)
CELLCEPT (198 patients)
TEMODAR (197 patients)
ASCORBIC ACID (192 patients)
TYLENOL (191 patients)
SUTENT (188 patients)
ALPRAZOLAM (185 patients)
ALLEGRA (185 patients)
BACTRIM DS (185 patients)
REBETOL (184 patients)
CLINDAMYCIN (184 patients)
IRON (184 patients)
MEROPENEM (184 patients)
PANTOPRAZOLE (183 patients)
ALKERAN (182 patients)
MIRALAX (181 patients)
ALDACTONE (181 patients)
CELEXA (180 patients)
MELPHALAN (179 patients)
MULTI-VITAMIN (179 patients)
METRONIDAZOLE (179 patients)
BENADRYL (178 patients)
VITAMIN E (177 patients)
ACCUTANE (176 patients)
ZYRTEC (175 patients)
METOCLOPRAMIDE (174 patients)
COLCHICINE (174 patients)
LAMIVUDINE (173 patients)
COLACE (172 patients)
CLONAZEPAM (172 patients)
TRAMADOL HCL (170 patients)
VINCRISTINE SULFATE (169 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about PANCYTOPENIA and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.